{"id":"W2026393945","doi":"10.1016/s0002-8703(03)00165-0","title":"Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study","year":2003,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Medicine; Eptifibatide; Tirofiban; Abciximab; Percutaneous coronary intervention; Enoxaparin sodium; Conventional PCI; Myocardial infarction; Internal medicine; Acute coronary syndrome; Low molecular weight heparin; Vitamin K antagonist; Unstable angina; Cardiology; Heparin; Surgery; Warfarin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005034491,0.001944307,0.005519868,0.0003270763,0.0003783947,0.002147566,0.001237925,0.002575007,0.001334252],"category_scores_gemma":[0.006033805,0.0009319045,0.006098106,0.0008047011,0.0006013526,0.001523957,0.000797551,0.002658364,0.0005603589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139619,"about_ca_system_score_gemma":0.001286129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002754228,"about_ca_topic_score_gemma":0.007886099,"domain_scores_codex":[0.9945294,0.00386072,0.0002612989,0.000342887,0.0006111194,0.0003944899],"domain_scores_gemma":[0.9960498,0.001649707,0.0007715829,0.0004136413,0.0003389653,0.0007762478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8256375,0.003563312,0.08293378,0.001225101,0.03849913,0.0005416601,0.0001655179,0.001868826,0.004667697,0.0003899173,0.007315425,0.03319216],"study_design_scores_gemma":[0.5405778,0.06356098,0.3157193,0.0004251235,0.06527749,0.0009960812,0.0002525222,0.002622781,0.001647342,0.001078893,0.007634252,0.0002074305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9707575,0.01696418,0.001229712,0.001507691,0.0004790367,0.000504243,0.003836427,0.0001178452,0.004603268],"genre_scores_gemma":[0.9840934,0.004270418,0.002101507,0.00216255,0.0006759769,0.0003763675,0.005357287,0.00005198166,0.0009105902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005519868,"threshold_uncertainty_score":0.02662528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08350052501595055,"score_gpt":0.3820065597237433,"score_spread":0.2985060347077927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}